PineTree Therapeutics

aid: pinetree-therapeutics
name: PineTree Therapeutics
description: 'Pinetree Therapeutics, Inc. is a preclinical-stage biotechnology company headquartered at West Cambridge Scientific
  Park, 767C Concord Ave, Cambridge, Massachusetts, developing next-generation targeted protein degraders (TPDs) built on
  its proprietary AbReptor platform. AbReptor degrades membrane-bound and extracellular proteins through target co-engagement,
  induced endocytosis, endolysosome formation and lysosomal degradation, aiming to overcome drug resistance and tumor recurrence
  in oncology, with additional application in inflammation and immunology. The company is advancing trispecific degraders
  and ADC-integrated programs, closed a $17M Series A in July 2024, and has entered a licensing partnership with AstraZeneca.
  It is a therapeutics developer rather than a software vendor: it publishes no public API, developer portal, SDK or machine-readable
  specification.'
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.pinetreetx.com/images/common/logo.png
url: https://raw.githubusercontent.com/api-evangelist/pinetree-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Oncology
- Drug Discovery
- Targeted Protein Degradation
- Preclinical
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/pinetree-therapeutics-domain-security.yml
- type: Website
  url: https://www.pinetreetx.com/
- type: News
  url: https://www.pinetreetx.com/en/news/news.php
- type: Team
  url: https://www.pinetreetx.com/en/team/leadership.php
- type: Careers
  url: https://www.pinetreetx.com/en/careers/job.php
- type: Investors
  url: https://www.pinetreetx.com/en/investors/investors.php
- type: Contact
  url: https://www.pinetreetx.com/en/communication/contact.php
- type: SecondaryMarket
  url: https://forgeglobal.com/pinetree-therapeutics_stock/
- type: LinkedIn
  url: https://www.linkedin.com/company/pinetree-therapeutics
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Pinetree Therapeutics is a preclinical-stage oncology drug developer whose product is a protein-degrader therapeutic,
    not software — its entire public site is seven brochure pages (team, science, news, careers, investors, contact) served
    from PHP with no /developers, /api, api./docs./developer. subdomain, sitemap, llms.txt or any /.well-known/ document.
  evidence:
  - url: https://www.pinetreetx.com/
    status: 200
  - url: https://www.pinetreetx.com/developers
    status: 404
  - url: https://www.pinetreetx.com/api
    status: 404
  - url: https://www.pinetreetx.com/openapi.json
    status: 404
  - url: https://www.pinetreetx.com/llms.txt
    status: 404
  - url: https://www.pinetreetx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.pinetreetx.com/.well-known/security.txt
    status: 404
  checked: '2026-08-05'